Target intelligence / Profile preview

Transcription factor p65 (RELA)

Target
RELA
Molecular classification
Transcription factor
01

Overview

Transcription factor p65, encoded by the RELA gene, is a key subunit of the nuclear factor kappa B (NF-κB) transcription factor complex, most commonly functioning as a heterodimer with the p50 subunit. In resting cells, this complex is sequestered in an inactive state in the cytoplasm by inhibitory IκB proteins. Upon stimulation by pro-inflammatory cytokines, pathogens, or cellular stress, IκB is phosphorylated and degraded, allowing the p65-containing dimer to translocate into the nucleus, where it binds to specific DNA response elements to drive the transcription of genes involved in immune responses, inflammation, cell survival, and proliferation.

Dysregulation and constitutive activation of p65 are strongly implicated in the pathogenesis of chronic inflammatory diseases, autoimmune disorders, and various cancers, where it promotes tumor cell survival, metastasis, and resistance to therapy. Consequently, p65 is a highly sought-after therapeutic target. Pharmacological modulation of this pathway is achieved through diverse mechanisms, including direct inhibition of p65 nuclear translocation, blocking its DNA-binding activity, preventing upstream IκB degradation, or modulating post-translational modifications like phosphorylation and acetylation. However, because of its essential role in normal immunity and cell survival, systemic and broad inhibition of p65 poses significant safety challenges, including immunosuppression and potential hepatotoxicity.

Other names
Nuclear factor NF-kappa-B p65 subunitNuclear factor of kappa light polypeptide gene enhancer in B-cells 3p65NF-kB p65NFKB3RELA proto-oncogene, NF-kB subunit
02

Mechanism of action

Inhibition of nuclear translocation, inhibition of DNA binding, inhibition of IκB degradation, inhibition of p65 acetylation, and inhibition of transactivation

03

Biological functions

Immune responseApoptosisInflammationCell survivalCell proliferationSignal transduction
04

Disease associations

CancerInflammationAutoimmune diseaseNeurodegenerative diseaseCardiovascular diseaseInfection
05

Safety considerations

Systemic immunosuppressionIncreased susceptibility to opportunistic infectionsHepatotoxicity (liver apoptosis)Impaired tissue healing and homeostasis
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

Nuclear p65 localizationp65 phosphorylation (e.g., Ser536)p65 acetylation (e.g., Lys310)NF-κB target gene expression (e.g., IL-6, IL-8, TNF-alpha, COX-2, iNOS)

Beyond the preview

Go deeper on Transcription factor p65 (RELA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription factor p65 (RELA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call